A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DEN

DEN 的多中心、双盲、随机、安慰剂对照、为期 28 天的研究

• 批准号: 7380767
• 负责人: DAVID A WALTZ
• 金额: $ 0.81万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380767
• 关键词: MULTICENTER; DOUBLE; BLIND; RANDOMIZED; PLACEBO

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and effectiveness of two dose strengths of INS37217, 20 mg and 60 mg, compared to placebo. Placebo is a sterile saline (salt water) solution. The study drug (INS37217 or placebo) will be administered via a nebulizer three times per day for up to 28 days to patients with CF lung disease. It is hoped that this study will help select the appropriate dose for further studies of INS37217 in cystic fibrosis patients.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是研究INS37217两种剂量强度（20mg和60mg）与安慰剂相比的安全性和有效性。安慰剂是一种无菌盐水溶液。研究药物（INS37217或安慰剂）将通过雾化器给予CF肺病患者，每天三次，长达28天。希望本研究能为INS37217在囊性纤维化患者中的进一步研究选择合适的剂量提供帮助。